DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1).

The report reviews targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved in targeted therapeutics and enlists all their major and minor projects.

The report assesses targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news and deals related to targeted therapeutics.

Key Topics Covered

Introduction Report Coverage Overview Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Companies Involved in Therapeutics Development Drug Profiles Dormant Products Discontinued Products Product Development Milestones Featured News & Press Releases

Companies Mentioned

Array BioPharma Inc AstraZeneca Plc Benevolentai Cambridge Ltd Daiichi Sankyo Co Ltd Dompe Farmaceutici SpA Genzyme Corp Handok Inc Ignyta Inc Loxo Oncology Inc Merck & Co Inc Nerviano Medical Sciences Srl Pfizer Inc Plexxikon Inc Purdue Pharma LP Rottapharm Biotech Srl Sienna Biopharmaceuticals Inc Tiziana Life Sciences Plc

For more information about this report visit https://www.researchandmarkets.com/research/wpjrl9/high_affinity?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005966/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:52 PM/DISC: 06/11/2018 01:51 PM

http://www.businesswire.com/news/home/20180611005966/en